Prediction: SRPT (Sarepta) is Bull to at least 72.81 Reasons: A good/decent Bull Pattern has emerged (Before closing) that is pointing upwards, and the Trends momentum is strong enough to push through the current resistance and reach the next resistance point of 72.81. And also, the main index for small biotech XBI is also showing bull signs. As you can see on...
SRPT looks like she will pop soon. The bollinger bands are contracted and are squeezing the keltner channel for a classic bollinger band squeeze. It is not a given which way this will pop, could go up or down..but a move is coming. There are pocket pivots under price Short is a bit over 9%. Negative volume is high on SRPT. Keltner Channels are...
SRPT showing bullish divergence, MACD & 9/20 crossover, and breakout/buy above $74.
Some of the biotech industry seems to be recovering after most suffering a long hard fall. SRPT gapped down, way down, did the dead cat bounce dance and regained a bit only to form a symmetrical triangle that broke to the downside. Then a descending triangle and has fallen down from each triangle the designated amount but could fall further. The low during these...
Breakaway Gap Hook Reversal Price Crossed SMA13 RSI divergence Williams %R Crossed -80 Entry 74 Stop 67 Target 100 I am not a PRO trader. I trade option to test my trading plan with small cost. The max Risk of each plan is less than 1% of my account. If you like this idea, please use SIM/Demo account to try it.
This is a stock ive lost on before - so be warned However, it seems so oversold and if price pushes lower I will likely re-enter, the stock has a strong pipeline of goods and has had some good news recently (Amondys 45 FDA approval) which hasnt really been reflected in the stock price. RSI is touching oversold Average Analyst price target is still $130 Price...
Hit that RedZone quick!
oscillators are done way oversold. we had an impulse move from the March low. A pennant about to breakout. MACD and Stoch overturning. Short term price target of $110.
Buying after a heavy sell off due to disappointing trial results Oversold (as per the chat the stock reacts strongly to being oversold) PPMO data expected in 2Q21 could prove a huge catalyst for shares to go higher Also - the company is posting strong sales growth (+40% this year) and peak sales estimates are over double current sales of some treatments...
This should in time fill the gap of $80 odd.. guna ride this wave back up..
If you understand the idea,🎯 press a thumb up! 👍👍👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!